Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel
NASDAQ:GRI

GRI Bio Q1 2025 Earnings Report

GRI Bio logo
$2.01 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.05 (+2.24%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

GRI Bio EPS Results

Actual EPS
-$162.40
Consensus EPS
-$114.24
Beat/Miss
Missed by -$48.16
One Year Ago EPS
N/A

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GRI Bio Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
8:30AM ET

Upcoming Earnings

GRI Bio's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

GRI Bio's Q1 2025 Press ReleasePress Release
(8-K)
GRI Bio's Q1 2025 Quarterly reportQuarterly report
(10-Q)

GRI Bio Earnings Headlines

Nano-X Imaging Maps Global Rollout for Nanox.ARC X, AI Imaging Platform
May 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30799538
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase-1036171505
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.tc pixel
June 3 at 1:00 AM  |  Brownstone Research (Ad)
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296710/0/en/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase.html
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...
May 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-1036155905
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294952/0/en/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-o.html
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

View GRI Bio Profile
Earnings Tools